This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
PDL BioPharma, Inc.
Drug Names(s): visilizumab, anti CD3, HuM291
Description: Protein Design Labs is developing this antibody for the treatment of graft-versus-host disease and, potentially, autoimmune diseases. It binds to the CD3 antigen, a part of the T cell receptor complex that can activate T cells.
Additional information available to subscribers only: